This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca (BCEL) Hisse Özeti

A clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Daha fazla detay

BCEL temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $4M )

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

+ 2 daha fazla risk

BCEL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW433,395 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

433,395 investors already sharing narratives

View all narratives

Atreca, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Atreca
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.09
52 Haftanın En Yüksek Seviyesi	US$1.18
52 Haftanın En Düşük Seviyesi	US$0.052
Beta	1.03
1 Aylık Değişim	-2.17%
3 Aylık Değişim	-40.00%
1 Yıllık Değişim	-92.17%
3 Yıllık Değişim	-98.85%
5 Yıllık Değişim	-99.47%
Halka arzdan bu yana değişim	-99.50%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Jul 23

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Dec 08

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Aug 08

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca press release (NASDAQ:BCEL): Q2 GAAP EPS of -$0.72 misses by $0.02. cash and cash equivalents and investments totaled $101.7 million.

Analiz Makalesi • Jun 18

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Apr 22

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Preliminary evidence shows that ATRC-101 helps those patients with higher target expression; 8 out of 12 patients (66%) who took ATCR-101 with H-score ≥ 50 responded. Phase 1b study was updated to recruit higher expression solid tumor patients for ATRC-101, with additional monotherapy and combination data expected in 2nd half of 2022. ATRC-101 being expanded to target solid tumor types that express the gene EphA2; IND-enabling studies ongoing with IND filing expected 1st half of 2023. Atreca Inc. had $148.1 million in cash as of December 31, 2021, enough cash to fund its operations through the 1st half of 2023.

Analiz Makalesi • Mar 05

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Jan 25

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Atreca's share price performance has been abysmal over the past 12 months - the stock has lost >85% of its value. The biotech IPOd in June 2019, raising >$100m to fund development of drugs developed by studying the successful immune responses of patients. ATRC-101 targets various solid tumors and is in a Phase 1 trial - initial data has been underwhelming with some safety issues and only six partial responses in 20 solid. There are other preclinical assets and a development partnership with Xencor to co-develop two drugs, as well as a Malaria therapy being developed with the Bill and Melinda Gates Foundation. Atreca stock may have punished too severely in my view and I can see an upside opportunity here - although drug development is a hit and miss industry, I see the risk reward here as potentially attractive for those with an appetite.

Seeking Alpha • Sep 10

Atreca: Safety Data Brought Down Stock

BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July. The pipeline is in very early stage.

Analiz Makalesi • Sep 02

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 14

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 29

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Analiz Makalesi • Dec 07

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Hissedar Getirileri

	BCEL	US Biotechs	US Pazar
7D	0%	0.7%	1.8%
1Y	-92.2%	37.1%	13.3%

Getiri vs. Endüstri: BCEL geçen yıl % 37.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: BCEL geçen yıl % 13.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BCEL's price volatile compared to industry and market?
BCEL volatility
BCEL Average Weekly Movement	21.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.8%

İstikrarlı Hisse Senedi Fiyatı: BCEL hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: BCEL 'nin haftalık oynaklığı son bir yılda 29% dan 21% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	90	John Orwin	www.atreca.com

Atreca, Inc. Temel Bilgiler Özeti

Atreca'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BCEL temel i̇stati̇sti̇kler
Piyasa değeri	US$3.57m
Kazançlar(TTM)	-US$97.76m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

BCEL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BCEL gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$97.76m
Kazançlar	-US$97.76m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.47
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

BCEL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/06/16 14:33
Gün Sonu Hisse Fiyatı	2024/06/14 00:00
Kazançlar	2023/09/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Atreca, Inc. 11 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Michael Ulz	Baird
Kumaraguru Raja	Brookline Capital Markets
John Newman	Canaccord Genuity

This company listing is no longer active

Atreca (BCEL) Hisse Özeti

Risk Analizi

Join community and earn perks

Atreca, Inc. Rakipler

Revelation Biosciences

Silo Pharma

Oncorus

ProtoKinetix

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Price target decreased to US$16.63

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Director notifies of intention to sell stock

New 90-day high: US$15.79

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Atreca, Inc. Temel Bilgiler Özeti

Kazanç ve Gelir

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları